Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenipatide versus placebo in adults with moderate-to-severe COPD
2026-525480-41-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Brenipatide with Placebo (2 arms). Primary endpoint: Change from baseline in pre-bronchodilator forced expiratory volume in 1 second. Planned start Sep 2026; status: authorised.
02
Drugs
brenipatide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2026-525480-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525480-41-00.